GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) --

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc (“GSK” or “the Company”) (NYSEGSK) and certain of its officers.

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 years. The vaccine targets five major serogroups of Neisseria meningitidis (A, B, C, W, and Y) which commonly cause invasive meningococcal disease (IMD).1,2

NEW YORK, Feb. 16, 2025 (GLOBE NEWSWIRE) --

NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) --

Glancy Prongay & Murray LLP reminds investors of the upcoming April 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired GSK plc. (“GSK” or the “Company”) (NYSEGSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”).

Law Offices of Howard G. Smith reminds investors of the upcoming April 7, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased GSK plc. (“GSK” or the “Company”) (NYSEGSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”).

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased GSK plc. (“GSK” or the “Company”) (NYSEGSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”). GSK investors have until April 7, 2025 to file a lead plaintiff motion.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired GSK plc. (“GSK” or the “Company”) (NYSEGSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”). GSK investors have until April 7, 2025 to file a lead plaintiff motion.

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc (“GSK” or “the Company”) (NYSEGSK) and certain of its officers.

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased GSK plc. (“GSK” or the “Company”) (NYSEGSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”). GSK investors have until April 7, 2025 to file a lead plaintiff motion.

SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all purchasers of the American Depository Receipts ("ADRs") of GSK PLC (NYSEGSK) between February 5, 2020 and August 14, 2022. GSK is a global pharmaceutical company that develops, manufactures, and markets vaccines and medicines worldwide.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc (“GSK” or “the Company”) (NYSEGSK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of GSK plc. (“GSK” or the “Company”) (NYSEGSK) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of GSK plc. (“GSK” or the “Company”) (NYSEGSK) investors concerning the Company’s possible violations of federal securities laws.

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of American Depositary Receipts (“ADRs”) of GSK plc (NYSEGSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the “Class Period”).

The Law Offices of Frank R. Cruz announces an investigation of GSK plc. (“GSK” or the “Company”) (NYSEGSK) on behalf of investors concerning the Company’s possible violations of federal securities laws.

GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST. Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. The acquisition includes lead molecule, IDRX-42, a highly selective KIT TKI being developed as a first- and second-line therapy for the treatment of GIST.

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NYSE:GSKNYSEGSK)(NASDAQ:AZNNASDAQAZN,(NASDAQ:GILDNASDAQ),(NYSE:BMYBMY) EQNX::TICKER_END

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NYSE:GSKNYSEGSK)(NASDAQ:AZNNASDAQAZN,(NYSE:ABBVNYSE),(NASDAQ:CRDFCRDF) EQNX::TICKER_END

PALM BEACH, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The demand for effective pancreatic cancer treatments is and has been undeniably high. The growing number of diagnoses, with the aggressive nature of the disease, fuels the market. This demand is further amplified by rising awareness and a focus on personalized medicine, leading to potentially more targeted and effective therapies. Pancreatic cancer remains a formidable foe, with the American Cancer Society estimating over 66,000 new diagnoses and a staggering 51,750 deaths in the US alone for 2024. This translates to 3% of all cancers and a grim 7% of all cancer fatalities, highlighting the urgent need for improved treatment options. The pancreatic cancer treatment market is driven by several factors, including the rising prevalence of obesity, alcohol consumption, and smoking. These lifestyle factors, combined with the growing geriatric population, are expected to fuel market growth. Additionally, personal or family history of pancreatitis and BRCA2 mutation predisposes individuals to pancreatic cancer, further driving demand for effective treatments. A recent report from S&S Insider said that the Pancreatic Cancer Treatment Market size is expected to reach USD 10.53 billion by 2032 and grow at a CAGR of 15.85%. The report continued: “On the supply side, pharmaceutical companies are actively involved in research and development… Moreover, 322 studies were under clinical trial according to clinicaltrail.com in their 3, and 4 phases. Governments also play a crucial role with increased funding for research initiatives and streamlined regulatory processes can accelerate the development and approval of new treatments. Collaborations between public and private entities foster progress, with the shared goal of improving patient outcomes. The overall market for pancreatic cancer treatments is expected to experience significant growth due to the increasing prevalence of the disease and the ongoing search for effective therapies. The development of innovative approaches… offers hope for patients and presents opportunities for pharmaceutical companies and research institutions.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), GSK plc NYSE: GSKNYSEGSK)(NASDAQ: AZNNASDAQAZN, Gilead Sciences, Inc. (NASDAQ: GILDNASDAQ), Bristol Myers Squibb (NYSE: BMYBMY).

PALM BEACH, Fla., Dec. 26, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The breast cancer drugs market is experiencing rapid expansion due to the diverse applications of drugs in various breast cancer treatment scenarios. Predominantly utilized before and after surgery, these drugs are pivotal in managing the disease. Significant research efforts are focused on targeted therapies tailored to specific breast cancer types, particularly those characterized by overexpression of human epidermal growth factor receptor 2 (HER2). HER2-positive breast cancers, constituting 15% to 20% of cases, exhibit heightened aggressiveness, necessitating targeted interventions. Targeted drug therapy, including immunotherapy, directly addresses proteins on cancer cells, impeding their growth and proliferation. With HER2-targeted drugs demonstrating efficacy in inhibiting tumor progression, the market witnesses a surge in the development and adoption of such therapies to meet the demand for more effective treatments in combating breast cancer. According to a report from BioSpace, the global breast cancer drugs market size, which was valued at USD 32.93 billion in 2023 is projected to surpass around USD 78.61 billion by 2033, registering a CAGR of 9.09% over the forecast period of 2024 to 2033. North America dominated the market with the largest revenue share of 38.61% in 2023. Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), GSK plc NYSE: GSKNYSEGSK)(NASDAQ: AZNNASDAQAZN, AbbVie (NYSE: ABBVNYSE), Cardiff Oncology, Inc. (NASDAQ: CRDFCRDF).

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NYSE:NVSNYSENVS)(NYSE:PFENYSEPFE,(NYSE:GSKNYSE),(NYSE:BMYBMY) EQNX::TICKER_END

PALM BEACH, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - One of the most common malignancies in the world today is gastric cancer. The incidence rate is influenced by various factors, including the aging of the population, dietary choices, lifestyle changes, and the prevalence of Helicobacter pylori infection. Growth in the market is driven by an increase in demand for diagnostic tools, therapies, and supporting care in tandem with a rise in the number of diagnosed cases. A recent report from MarketsAndMarkets projected that the global gastric cancer market accounted for USD 3.01 billion in 2023 and is expected to reach USD 18.43 billion by 2034 with a CAGR of 17.92% during the forecast period 2024-2034. The report said: “The market will grow due to the rising incidence of gastric cancer, improvements in diagnostic technologies, emerging treatments and therapies, personalized medicine and precision medicine, government funding and initiatives, and technological advancements in surgery and minimally invasive procedures. Growth in the market is driven by an increase in demand for diagnostic tools, therapies, and supporting care in tandem with a rise in the number of diagnosed cases. For instance, in January 2024, Roche revealed encouraging findings from the Phase III RAINBOW research, which assessed the safety and effectiveness of ramucirumab when combined with chemotherapy to treat advanced stomach or gastroesophageal junction (GEJ) cancer.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), Novartis AG NYSE: NVSNYSENVS)(NYSE: PFENYSEPFE, GSK plc (NYSE: GSKNYSE), Bristol Myers Squibb (NYSE: BMYBMY).

GSK plc (LSE/NYSE: GSK) today announced statistically significant and clinically meaningful overall survival (OS) results from a planned interim analysis of the DREAMM-7 trial evaluating belantamab mafodotin in combination with bortezomib plus dexamethasone (BVd) versus daratumumab in combination with bortezomib plus dexamethasone (DVd) as a second line or later treatment for relapsed or refractory multiple myeloma. These data were featured today in an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.